Pharmaceutical compositions comprising 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5- yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1) in Form I and a solid dispersion comprising substantially amorphous N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4- oxo-1H-quinoline-3-carboxamide (Compound 2), methods of treating, lessening the severity of, or symptomatically treating CFTR mediated diseases, such as cystic fibrosis, methods of manufacturing, methods of administering, and kits thereof are disclosed.
含有3-(6-(1-(2,2-二
氟苯并[d][1,3]二氧杂环戊-5-基)环丙基羧胺基)-3-
甲基吡啶-2-基)
苯甲酸(化合物1)的制药组合物,形式I和包含基本无定形N-(5-羟基-2,4-二
叔丁基苯基)-4-氧代-1H-
喹啉-3-羧酰胺(化合物2)的固体分散体,用于治疗、减轻或症状性治疗CFTR介导的疾病,如囊性纤维化,公开了制造方法、给药方法和相关的试剂盒。